Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D8DD
|
|||
| Former ID |
DAP000357
|
|||
| Drug Name |
Sufentanil
|
|||
| Synonyms |
Chronogesic; Sufentanilum; Sufentanyl; Sulfentanil; Sulfentanyl; R 30730; R-30730; Sufenta (TN); Sufentanilum [INN-Latin]; Sufentil (TN); Sufentanil (USAN/INN); Sufentanil [USAN:BAN:INN]; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide; N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide; N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Analgesia [ICD-11: MB40.8; ICD-10: R20.0; ICD-9: 338] | Approved | [1] | |
| Therapeutic Class |
Anesthetics
|
|||
| Company |
Janssen Pharmaceutica
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H30N2O2S
|
|||
| Canonical SMILES |
CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC
|
|||
| InChI |
1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3
|
|||
| InChIKey |
GGCSSNBKKAUURC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 56030-54-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10222, 6311194, 7980695, 8177237, 14804981, 34707309, 46504737, 47207596, 47252825, 47326870, 47624342, 47846995, 48416563, 50064909, 50787758, 57312595, 85209320, 103189274, 103924757, 104337672, 111978170, 117568208, 124953716, 124953717, 127949007, 134222396, 134337667, 135003073, 137002461, 139212423, 160964052, 164035747, 175268924, 175443463, 178100513, 179150640, 185971931, 198991634, 210274958, 210280596, 223398861, 224247843, 226414514, 241097876, 250113166, 251880715, 252481124
|
|||
| ChEBI ID |
CHEBI:9316
|
|||
| ADReCS Drug ID | BADD_D02082 ; BADD_D02083 | |||
| SuperDrug ATC ID |
N01AH03
|
|||
| SuperDrug CAS ID |
cas=056030547
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor (OPR) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.